Pfizer closes in on $7.3 billion takeover of anti-obesity drugmaker Metsera

Pfizer is closing in on a potential $7.3 billion takeover of weight-loss drug developer Metsera, the Financial Times reported on Sunday, citing unidentified sources.
Pfizer, one of the largest pharmaceutical companies in the United States, will acquire New York City-based Metsera for $47.50 per share in cash, with an additional $22.50 per share contingent on the achievement of certain performance milestones, the newspaper said.
FT reported that the announcement could come as early as Monday, unless deal talks fall through.
Reuters could not immediately confirm the report. Pfizer and Metsera did not immediately respond to a Reuters request for comment outside regular business hours.